In short

Both are approved for type 2 diabetes and both are weekly injections. Ozempic is semaglutide, acting on the GLP-1 receptor. Mounjaro is tirzepatide, acting.

By Alsen Walker · Updated September 20, 2026

By Alsen Walker · Editorially reviewed on 25 August 2026 · Not medically reviewed by a clinician

Both are approved for type 2 diabetes and both are weekly injections. Ozempic is semaglutide, acting on the GLP-1 receptor. Mounjaro is tirzepatide, acting on GLP-1 and GIP receptors. For diabetes specifically, the choice usually comes down to your glycaemic targets, your other conditions, and what your plan covers.

If you take insulin or a sulfonylurea alongside either of these, low blood sugar becomes more likely. Those doses often need adjusting when a GLP-1 is added, and that is a prescriber decision to raise early rather than discover through symptoms. Confusion, shaking, sweating or a racing heart that eases after eating needs checking with a meter.

For how this fits alongside the other comparisons, and what actually decides the choice, see Comparing GLP-1 Medications: How to Actually Choose.

Same category, different molecules

Both improve glycaemic control and both commonly produce weight loss alongside it, which is part of why they are used in type 2 diabetes.

Tirzepatide engages a second receptor pathway. Whether that produces a consistent advantage for a given person is a clinical judgement rather than a settled fact, and it is not something an article can decide for you.

What your prescriber weighs

How far your A1c is from target. The gap influences which agent and what else is needed alongside.

Cardiovascular and kidney history. Some agents in this broader class carry approved indications beyond glucose control, and those indications can be decisive both clinically and for coverage.

Weight. Both commonly produce weight loss, which is usually desirable in type 2 diabetes.

Your other medications. Particularly insulin and sulfonylureas, for the reason above.

Tolerability. The gastrointestinal profile is similar for both, and individual response varies.

Coverage, which often decides it

For diabetes, coverage is generally more straightforward than for weight management, because glucose control is a standard covered indication rather than an optional benefit.

Plans still differ on which they prefer, and step therapy is common. Check your formulary before the conversation, since knowing which is preferred changes what is realistic.

The weight loss question

These are prescribed for diabetes, and the related weight-management products are separate brands with separate approved indications and separate coverage.

Asking for a diabetes product to be covered for weight loss when you do not have diabetes is not a workaround, and requesting a diagnosis you do not have is a false claim on your record with consequences that outlast the prescription.

Monitoring

Expect A1c checks and, depending on your history, kidney function. If you monitor glucose at home, expect readings to change as the medication takes effect, particularly in the first weeks and after each dose increase.

Report low readings rather than adjusting other medications yourself.

If you take insulin or a sulfonylurea alongside either, low blood sugar becomes more likely and doses often need adjusting, which belongs in the monitoring conversation. For the weight-management versions of these drugs, see Zepbound versus Wegovy.

Frequently asked questions

Which lowers A1c more?
A question for your prescriber against your own targets and history rather than a general ranking.

Will either cause low blood sugar?
Unlikely alone; more likely combined with insulin or a sulfonylurea. Raise it before starting.

Can I switch between them?
Yes, with re-titration and usually a new authorization.

Do they both help with weight?
Both commonly produce weight loss in people with type 2 diabetes.

Do I still need metformin?
Often yes, and that is your prescriber’s decision based on your control and history.

Which is better if I have heart disease?
Approved cardiovascular indications differ between products in this class. Tell your prescriber your full history, since it may be decisive.

Sources and further reading

  1. Novo Nordisk. Ozempic (semaglutide) injection: US Prescribing Information. www.novo-pi.com
  2. MedlinePlus (US National Library of Medicine). Semaglutide injection: drug information. medlineplus.gov
  3. Eli Lilly and Company. Mounjaro (tirzepatide) injection: US Prescribing Information. pi.lilly.com
  4. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Prescription medications to treat overweight and obesity. www.niddk.nih.gov

GLP1Hub content is for general information and is not medical advice. Prices and coverage rules change often, so confirm current details with the provider, your insurer and your prescriber. See our editorial standards and medical disclaimer.

More in Comparisons

All Comparisons guides →

Alsen Walker is a health writer and researcher at GLP1Hub with five years of experience researching and writing health and medical content. He works in a medical-field role alongside his undergraduate studies. At GLP1Hub he researches GLP-1 weight loss programs, pricing and insurance rules, and checks claims against FDA prescribing information, published clinical trials and official government sources. Alsen is not a physician, and his articles are general information, not medical advice.